文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肺鳞状细胞癌中淋巴结指标的预后价值:基于监测、流行病学和最终结果(SEER)数据库的分析

Prognostic value of lymph node metrics in lung squamous cell carcinoma: an analysis of the SEER database.

作者信息

Liu Lei, Zhang Qiao, Jin Shuai, Xie Lang

机构信息

School of Biology & Engineering (School of Health Medicine Modern Industry), Guizhou Medical University, Guiyang, 561113, China.

Medical Department, The Second People's Hospital of Guiyang(Jinyang Hospital), Guiyang, 550081, China.

出版信息

World J Surg Oncol. 2024 Dec 28;22(1):351. doi: 10.1186/s12957-024-03639-4.


DOI:10.1186/s12957-024-03639-4
PMID:39731070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11681691/
Abstract

INTRODUCTION: Although the Tumor-Node-Metastasis (TNM) staging system is widely used for staging lung squamous cell carcinoma (LSCC), the TNM system primarily emphasizes tumor size and metastasis, without adequately considering lymph node involvement. Consequently, incorporating lymph node metastasis as an additional prognostic factor is essential for predicting outcomes in LSCC patients. METHODS: This retrospective study included patients diagnosed with LSCC between 2004 and 2018 and was based on data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. The primary endpoint of the study was cancer-specific survival (CSS), and demographic characteristics, tumor characteristics, and treatment regimens were incorporated into the predictive model. The study focused on the value of indicators related to pathological lymph node testing, including the lymph node ratio (LNR), regional node positivity (RNP), and lymph node examination count (RNE), in the prediction of cancer-specific survival in LSCC. A prognostic model was established using a multivariate Cox regression model, and the model was evaluated using the C index, Kaplan-Meier, the Akaike information criterion (AIC), decision curve analysis (DCA), continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI), and the predictive efficacy of different models was compared. RESULTS: A total of 14,200 LSCC patients (2004-2018) were divided into training and validation cohorts. The 10-year CSS rate was approximately 50%, with no significant survival differences between cohorts (p = 0.8). The prognostic analysis revealed that models incorporating LNR, RNP, and RNE demonstrated superior performance over the TNM model. The LNR and RNP models demonstrated better model fit, discrimination, and reclassification, with AUC values of 0.695 (training) and 0.665 (validation). The RNP and LNR models showed similar predictive performance, significantly outperforming the TNM and RNE models. Calibration curves and decision curve analysis confirmed the clinical utility and net benefit of the LNR and RNP models in predicting long-term CSS for LSCC patients, highlighting their value in clinical decision-making. CONCLUSION: This study confirms that RNP status is an independent prognostic factor for CSS in LSCC, with predictive efficacy comparable to LNR, with both models enhancing survival prediction beyond TNM staging.

摘要

引言:尽管肿瘤-淋巴结-转移(TNM)分期系统广泛用于肺鳞状细胞癌(LSCC)的分期,但TNM系统主要强调肿瘤大小和转移情况,未充分考虑淋巴结受累情况。因此,将淋巴结转移作为额外的预后因素对于预测LSCC患者的预后至关重要。 方法:这项回顾性研究纳入了2004年至2018年间被诊断为LSCC的患者,数据来自美国国立癌症研究所的监测、流行病学和最终结果(SEER)数据库。该研究的主要终点是癌症特异性生存(CSS),并将人口统计学特征、肿瘤特征和治疗方案纳入预测模型。该研究重点关注与病理淋巴结检测相关指标的价值,包括淋巴结比率(LNR)、区域淋巴结阳性率(RNP)和淋巴结检查计数(RNE),用于预测LSCC患者的癌症特异性生存。使用多变量Cox回归模型建立预后模型,并使用C指数、Kaplan-Meier、赤池信息准则(AIC)、决策曲线分析(DCA)、连续净重新分类改善(NRI)和综合判别改善(IDI)对模型进行评估,并比较不同模型的预测效能。 结果:共有14200例LSCC患者(2004 - 2018年)被分为训练队列和验证队列。10年CSS率约为50%,各队列之间的生存差异无统计学意义(p = 0.8)。预后分析显示,纳入LNR、RNP和RNE的模型表现优于TNM模型。LNR和RNP模型显示出更好的模型拟合、判别能力和重新分类能力,训练集AUC值为0.695,验证集为0.665。RNP和LNR模型显示出相似的预测性能,显著优于TNM和RNE模型。校准曲线和决策曲线分析证实了LNR和RNP模型在预测LSCC患者长期CSS方面的临床实用性和净效益,突出了它们在临床决策中的价值。 结论:本研究证实RNP状态是LSCC患者CSS的独立预后因素,其预测效能与LNR相当,这两种模型均能增强TNM分期之外的生存预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/890a22a14818/12957_2024_3639_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/0ffbdf3a1787/12957_2024_3639_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/922fa5dacc69/12957_2024_3639_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/890a22a14818/12957_2024_3639_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/0ffbdf3a1787/12957_2024_3639_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/922fa5dacc69/12957_2024_3639_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11681691/890a22a14818/12957_2024_3639_Figc_HTML.jpg

相似文献

[1]
Prognostic value of lymph node metrics in lung squamous cell carcinoma: an analysis of the SEER database.

World J Surg Oncol. 2024-12-28

[2]
Dynamic nomograms combining N classification with ratio-based nodal classifications to predict long-term survival for patients with lung adenocarcinoma after surgery: a SEER population-based study.

BMC Cancer. 2021-8-4

[3]
Lymph node ratio emerges as a pivotal prognostic determinant for cancer-specific survival amidst individuals diagnosed with stage N1 and N2 non-small cell lung carcinoma: A population-based retrospective cohort study.

Medicine (Baltimore). 2025-4-18

[4]
A Prognostic Model Based on the Log Odds Ratio of Positive Lymph Nodes Predicts Prognosis of Patients with Rectal Cancer.

J Gastrointest Cancer. 2024-9

[5]
Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.

BMC Cancer. 2025-1-23

[6]
Prognostic nomogram based on the lymph node metastasis indicators for patients with bladder cancer: A SEER population-based study and external validation.

Cancer Med. 2023-3

[7]
Prognostic value of a modified pathological staging system for gastric cancer based on the number of retrieved lymph nodes and metastatic lymph node ratio.

PeerJ. 2024

[8]
Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma.

JAMA Dermatol. 2019-7-1

[9]
Development and Validation of Prognostic Nomograms Based on Lymph Node Ratio for Young Patients with Gastric Cancer: A SEER-Based Study.

Technol Cancer Res Treat. 2023

[10]
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.

Lung Cancer. 2018-5-23

本文引用的文献

[1]
A survival nomogram model for patients with resectable non-small cell lung cancer and lymph node metastasis (N1 or N2) based on the Surveillance, Epidemiology, and End Results Database and single-center data.

Transl Lung Cancer Res. 2024-3-29

[2]
Development and validation of a population-based model for predicting the regional lymph node metastasis in adolescent differentiated thyroid carcinoma.

Oral Oncol. 2021-10

[3]
Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.

Mod Pathol. 2021-11

[4]
Decision curve analysis to evaluate the clinical benefit of prediction models.

Spine J. 2021-10

[5]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[6]
Positive Lymph Nodes in Adrenocortical Carcinoma: What Does It Mean?

World J Surg. 2021-1

[7]
Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study.

J Thorac Oncol. 2019-8-20

[8]
Regional Lymph Node Involvement Is Associated With Poorer Survivorship in Patients With Chondrosarcoma: A SEER Analysis.

Clin Orthop Relat Res. 2019-11

[9]
Comparison between lymph node station- and zone-based classification for the future revision of node descriptors proposed by the International Association for the Study of Lung Cancer in surgically resected patients with non-small-cell lung cancer.

Eur J Cardiothorac Surg. 2019-11-1

[10]
Abandoning the Notion of Non-Small Cell Lung Cancer.

Trends Mol Med. 2019-5-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索